Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.

Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML.

Pediatr Blood Cancer. 2018 Jul;65(7):e27034. doi: 10.1002/pbc.27034. Epub 2018 Mar 12.

PMID:
29528181
2.

ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients.

Stieglitz E, Dinh T, Phelps AS, Pampaloni MH, Olshen AB, Robbins E.

J Pediatr Hematol Oncol. 2018 May;40(4):290-294. doi: 10.1097/MPH.0000000000001094.

PMID:
29432308
3.

Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.

Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML.

Nat Commun. 2017 Dec 19;8(1):2127. doi: 10.1038/s41467-017-02178-9.

4.

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.

Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15.

5.

Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient.

Wang SJ, Asthana S, van Zante A, Heaton CM, Phuchareon J, Stein L, Higuchi S, Kishimoto T, Chiu CY, Olshen AB, McCormick F, Tetsu O.

Oral Oncol. 2017 Jun;69:1-10. doi: 10.1016/j.oraloncology.2017.03.020. Epub 2017 Apr 3.

6.

Quantitative proteomic analyses of mammary organoids reveals distinct signatures after exposure to environmental chemicals.

Williams KE, Lemieux GA, Hassis ME, Olshen AB, Fisher SJ, Werb Z.

Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):E1343-51. doi: 10.1073/pnas.1600645113. Epub 2016 Feb 22.

7.

Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia.

Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML.

Nat Genet. 2016 Jan;48(1):101. doi: 10.1038/ng0116-101a. No abstract available.

PMID:
26711114
8.

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach.

Korkola JE, Heck S, Olshen AB, Feldman DR, Reuter VE, Houldsworth J, Bosl GJ, Chaganti RS.

PLoS One. 2015 Dec 1;10(12):e0142846. doi: 10.1371/journal.pone.0142846. eCollection 2015.

9.

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, Schultz N, Taylor BS.

Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.

10.

The genomic landscape of juvenile myelomonocytic leukemia.

Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber T, Golub T, Stegmaier K, Loh ML.

Nat Genet. 2015 Nov;47(11):1326-1333. doi: 10.1038/ng.3400. Epub 2015 Oct 12. Erratum in: Nat Genet. 2015 Nov;47(11):1333. Nat Genet. 2016 Jan;48(1):101.

11.

DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors.

Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, Bell RJA, Smirnov IV, Reis GF, Phillips JJ, Barnes MJ, Idbaih A, Alentorn A, Kloezeman JJ, Lamfers MLM, Bollen AW, Taylor BS, Molinaro AM, Olshen AB, Chang SM, Song JS, Costello JF.

Cancer Cell. 2015 Sep 14;28(3):307-317. doi: 10.1016/j.ccell.2015.07.012.

12.

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.

Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, Chung J, Wang NJ, Kakavand H, Mann GJ, Thompson JF, Wiesner T, Roy R, Olshen AB, Gagnon A, Gray JW, Huh N, Hur JS, Busam KJ, Scolyer RA, Cho RJ, Murali R, Bastian BC.

Nat Genet. 2015 Oct;47(10):1194-9. doi: 10.1038/ng.3382. Epub 2015 Sep 7.

13.

DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly.

Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, van Essen HF, Eijk PP, Rustenburg F, Meijer GA, Reijneveld JC, Wesseling P, Pinkel D, Albertson DG, Ylstra B.

Genome Res. 2014 Dec;24(12):2022-32. doi: 10.1101/gr.175141.114. Epub 2014 Sep 18.

14.

Changes in abundance of oral microbiota associated with oral cancer.

Schmidt BL, Kuczynski J, Bhattacharya A, Huey B, Corby PM, Queiroz EL, Nightingale K, Kerr AR, DeLacure MD, Veeramachaneni R, Olshen AB, Albertson DG.

PLoS One. 2014 Jun 2;9(6):e98741. doi: 10.1371/journal.pone.0098741. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e106297. Muy-Teck The [removed].

15.

Recurrent epimutations activate gene body promoters in primary glioblastoma.

Nagarajan RP, Zhang B, Bell RJ, Johnson BE, Olshen AB, Sundaram V, Li D, Graham AE, Diaz A, Fouse SD, Smirnov I, Song J, Paris PL, Wang T, Costello JF.

Genome Res. 2014 May;24(5):761-74. doi: 10.1101/gr.164707.113. Epub 2014 Apr 7.

16.

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.

Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF.

Science. 2014 Jan 10;343(6167):189-193. doi: 10.1126/science.1239947. Epub 2013 Dec 12.

17.

The translational landscape of the mammalian cell cycle.

Stumpf CR, Moreno MV, Olshen AB, Taylor BS, Ruggero D.

Mol Cell. 2013 Nov 21;52(4):574-82. doi: 10.1016/j.molcel.2013.09.018. Epub 2013 Oct 10.

18.

Assessing gene-level translational control from ribosome profiling.

Olshen AB, Hsieh AC, Stumpf CR, Olshen RA, Ruggero D, Taylor BS.

Bioinformatics. 2013 Dec 1;29(23):2995-3002. doi: 10.1093/bioinformatics/btt533. Epub 2013 Sep 18.

19.

β1-Integrin via NF-κB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer.

Nam JM, Ahmed KM, Costes S, Zhang H, Onodera Y, Olshen AB, Hatanaka KC, Kinoshita R, Ishikawa M, Sabe H, Shirato H, Park CC.

Breast Cancer Res. 2013;15(4):R60.

20.

A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D.

Nat Med. 2013 May;19(5):619-25. doi: 10.1038/nm.3175. Epub 2013 Apr 14.

21.

Pattern discovery and cancer gene identification in integrated cancer genomic data.

Mo Q, Wang S, Seshan VE, Olshen AB, Schultz N, Sander C, Powers RS, Ladanyi M, Shen R.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4245-50. doi: 10.1073/pnas.1208949110. Epub 2013 Feb 21.

22.

Integrative subtype discovery in glioblastoma using iCluster.

Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, Huse J, Ladanyi M, Sander C.

PLoS One. 2012;7(4):e35236. doi: 10.1371/journal.pone.0035236. Epub 2012 Apr 23.

23.

Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis.

Bhattacharya A, Roy R, Snijders AM, Hamilton G, Paquette J, Tokuyasu T, Bengtsson H, Jordan RC, Olshen AB, Pinkel D, Schmidt BL, Albertson DG.

Clin Cancer Res. 2011 Nov 15;17(22):7024-34. doi: 10.1158/1078-0432.CCR-11-1944. Epub 2011 Nov 8.

24.

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.

Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, Weis-Garcia F, Tam W, Shaknovich R, Melnick A, Himanen JP, Chaganti RS, Wendel HG.

Cell. 2011 Oct 28;147(3):554-64. doi: 10.1016/j.cell.2011.09.035.

25.

Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.

Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, Rusch V, Ladanyi M.

J Thorac Oncol. 2011 May;6(5):864-74.

26.

Parent-specific copy number in paired tumor-normal studies using circular binary segmentation.

Olshen AB, Bengtsson H, Neuvial P, Spellman PT, Olshen RA, Seshan VE.

Bioinformatics. 2011 Aug 1;27(15):2038-46. doi: 10.1093/bioinformatics/btr329. Epub 2011 Jun 11.

27.

Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles.

Ostrovnaya I, Seshan VE, Olshen AB, Begg CB.

Bioinformatics. 2011 Jun 15;27(12):1698-9. doi: 10.1093/bioinformatics/btr267. Epub 2011 May 5.

28.

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW.

Nat Med. 2011 Apr;17(4):500-3. doi: 10.1038/nm.2344. Epub 2011 Apr 3.

29.

Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities.

Affer M, Dao S, Liu C, Olshen AB, Mo Q, Viale A, Lambek CL, Marr TG, Clarkson BD.

J Oncol. 2011;2011:798592. doi: 10.1155/2011/798592. Epub 2011 Feb 23.

30.

Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI.

Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC.

Integr Biol (Camb). 2011 Apr;3(4):490-6. doi: 10.1039/c0ib00089b. Epub 2011 Mar 18.

31.

Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.

Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Clin Cancer Res. 2011 Jan 1;17(1):122-33. doi: 10.1158/1078-0432.CCR-10-0253.

32.

Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients.

Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R.

Cancer Res. 2011 Jan 15;71(2):550-60. doi: 10.1158/0008-5472.CAN-10-1229. Epub 2010 Nov 22.

33.

Copy number and gene expression differences between African American and Caucasian American prostate cancer.

Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, Yu JZ, Dash A, Jean-Gilles J, Reuter V, Gerald WL, Lee P, Osman I.

J Transl Med. 2010 Jul 22;8:70. doi: 10.1186/1479-5876-8-70.

34.

A classification model for distinguishing copy number variants from cancer-related alterations.

Ostrovnaya I, Nanjangud G, Olshen AB.

BMC Bioinformatics. 2010 Jun 2;11:297. doi: 10.1186/1471-2105-11-297.

35.

Genetic analysis of the early natural history of epithelial ovarian carcinoma.

Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J.

PLoS One. 2010 Apr 26;5(4):e10358. doi: 10.1371/journal.pone.0010358.

36.

A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data.

Ostrovnaya I, Olshen AB, Seshan VE, Orlow I, Albertson DG, Begg CB.

Stat Med. 2010 Jul 10;29(15):1608-21. doi: 10.1002/sim.3866.

37.

Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.

Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, Patil S, Reuter VE, Bosl GJ, Chaganti RS.

J Clin Oncol. 2009 Nov 1;27(31):5240-7. doi: 10.1200/JCO.2008.20.0386. Epub 2009 Sep 21.

38.

Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis.

Shen R, Olshen AB, Ladanyi M.

Bioinformatics. 2009 Nov 15;25(22):2906-12. doi: 10.1093/bioinformatics/btp543. Epub 2009 Sep 16. Erratum in: Bioinformatics. 2010 Jan 15;26(2):292-3.

39.

Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.

Houldsworth J, Petlakh M, Olshen AB, Chaganti RS.

Leuk Lymphoma. 2008 Nov;49(11):2170-80. doi: 10.1080/10428190802428369.

PMID:
19021061
40.

The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.

Filion C, Motoi T, Olshen AB, Laé M, Emnett RJ, Gutmann DH, Perry A, Ladanyi M, Labelle Y.

J Pathol. 2009 Jan;217(1):83-93. doi: 10.1002/path.2445.

41.

Associations among multiple markers and complex disease: models, algorithms, and applications.

Assimes TL, Olshen AB, Narasimhan B, Olshen RA.

Adv Genet. 2008;60:437-64. doi: 10.1016/S0065-2660(07)00416-6. Review.

PMID:
18358329
42.

Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.

Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein RJ, Clark AG, Norton L, Dean M, Boyd J, Offit K.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4340-5. doi: 10.1073/pnas.0800441105. Epub 2008 Mar 7.

43.

Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping.

Olshen AB, Gold B, Lohmueller KE, Struewing JP, Satagopan J, Stefanov SA, Eskin E, Kirchhoff T, Lautenberger JA, Klein RJ, Friedman E, Norton L, Ellis NA, Viale A, Lee CS, Borgen PI, Clark AG, Offit K, Boyd J.

BMC Genet. 2008 Feb 5;9:14. doi: 10.1186/1471-2156-9-14.

44.

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.

Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, Fleisher M, Hoffman J, Jhanwar S, Young JW, Nimer SD, Boruchov AM.

Blood. 2008 Apr 1;111(7):3403-6. doi: 10.1182/blood-2007-11-125526. Epub 2008 Jan 23.

45.

In vivo differentiation and genomic evolution in adult male germ cell tumors.

Korkola JE, Heck S, Olshen AB, Reuter VE, Bosl GJ, Houldsworth J, Chaganti RS.

Genes Chromosomes Cancer. 2008 Jan;47(1):43-55.

PMID:
17943972
46.

A faster circular binary segmentation algorithm for the analysis of array CGH data.

Venkatraman ES, Olshen AB.

Bioinformatics. 2007 Mar 15;23(6):657-63. Epub 2007 Jan 18.

PMID:
17234643
47.

Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells.

Chadalavada RS, Korkola JE, Houldsworth J, Olshen AB, Bosl GJ, Studer L, Chaganti RS.

Stem Cells. 2007 Mar;25(3):771-8. Epub 2006 Nov 30.

48.

Identifying site-specific metastasis genes and functions.

Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, Olshen AB, Gerald WL, Massagué J.

Cold Spring Harb Symp Quant Biol. 2005;70:149-58.

PMID:
16869748
49.

p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.

Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi D, Sabbatini P, Soslow RA.

Int J Gynecol Cancer. 2006 Mar-Apr;16(2):849-53.

PMID:
16681772
50.

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

López-Ríos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M.

Cancer Res. 2006 Mar 15;66(6):2970-9.

Supplemental Content

Loading ...
Support Center